| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1816
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 |
| filingDate |
1999-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15836ea75216a6660433d61a09832963
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62f208a2ad2d9c9c0159aa7f6dc1afcb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb6961df046956e2418de81d879efc61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23c892b9ff87b9f7c6e3d90e2949d704 |
| publicationDate |
2002-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2002028236-A1 |
| titleOfInvention |
Erythropo ietin liposomal dispersion |
| abstract |
The present invention relates to a liposome based formulation of erythropoietin comprising: n (a) an effective amount of an erythropoietin; n (b) a lipidic phase comprising: n (i) lecithin or hydrogenated lecithin; n (ii) optionally, a charged electropositive or electronegative lipid compound; and n (iii) cholesterol or a derivative thereof selected from cholesterol esters, polyethylene glycol derivatives of cholesterol (PEG-cholesterols), and organic acid derivatives of cholesterols; and n (c) a phosphate buffer. n The liposome based parenteral dosage form of the invention is prepared by means of an ethanol injection technique. The composition avoids the need for use of human serum albumin and exhibits superior stability. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9682054-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006128800-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011070294-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101154442-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008113015-A1 |
| priorityDate |
1998-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |